drugset

drugset / Trial / NCT06662097

A Study of Bevonescein in Patients Undergoing Abdominopelvic Surgery

NCT06662097 ↗

Phase 2 Recruiting 64 enrolled Alume Biosciences, Inc.

Non-randomizedSequentialOpen-labelPrevention

Summary

Feasibility study of Bevonescein to highlight Nerves and Ureter in patients undergoing Minimally Invasive Surgery

Timeline

Start: 2024-10-16
Primary completion: 2025-06
Completion: 2025-09

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Bevonescein	Peptide	—	Intravenous

Indications